Table 2. Treatment outcomes.
| Treatment outcomes | Median (mo) | 2 y (%) | 3 y (%) | 5 y (%) | Log-rank p -value | |
|---|---|---|---|---|---|---|
| LC | ||||||
| LC according to tumor site | Anterior cranial fossa | NA | 50% (13.7%, 78.5%) | 50% (13.7%, 78.5%) | NA | 0.42 |
| Middle cranial fossa | 53.7 (32.8, 60.1) | 90.9% (50.8%, 98.7%) | 68.2% (16.3%, 92.2%) | 45.5% (6.1%, 80.1%) | ||
| Posterior cranial fossa | NA | 63.3% (21.5%, 87.3%) | 63.3% (21.5%, 87.3%) | 63.3% (21.5%, 87.3%) | ||
| Convexity | 109.6 (51.8, 167.8) | 90.6% (67.3%, 97.6%) | 84.1% (57.7%, 94.7%) | 74.8% (43.5%, 90.4%) | ||
| Parasagittal | 46.7 (22.2, 114.3) | 88.9% (43.3%, 98.4%) | 66.7% (28.17%, 87.8%) | 41.7% (10.9%, 70.8%) | ||
| Temporal | NA | 64.3% (15.1%, 90.2%) | 64.3% (15.1%, 90.2%) | 64.3% (15.1%, 90.2%) | ||
| Others | NA | 50.0% (0.6%, 91.0%) | 50.0% (0.6%, 91.0%) | NA | ||
| LC according to initial symptoms | No | 53.7 (32.8, 93.1) | 78.7% (57.5%, 90.1%) | 58.4% (32.5%, 77.3%) | 34.1% (7.8%, 63.6%) | 0.39 |
| Yes | 88.7 (46.7, 167.8) | 77.5% (59.9%, 88.1%) | 73.6% (55.1%, 85.5%) | 64.1% (43.3%, 78.9%) | ||
| LC according to age (y) | ≤ 60 | 88.7 (46.7, 167.8) | 75.7% (56.8%, 87.2%) | 71.3% (51.2%, 84.2%) | 65.8% (44.3%, 80.6%) | 0.73 |
| > 60 | 51.8 (32.8, 109.6) | 80.4% (60.8%, 90.9%) | 64.8% (41.3%, 80.8%) | 39.3% (14.7%, 63.4%) | ||
| LC according to gender | Female | 60.1 (37.4, 114.3) | 85.9% (68.6%, 94.1%) | 75.2% (52.7%, 88.1%) | 56.4% (31.4%, 75.4%) | 0.59 |
| Male | 88.7 (35.0, 167.8) | 72.9% (54.1%, 85%) | 64.5% (44.2%, 79.1%) | 58.1% (36.1%, 74.8%) | ||
| LC according to smoking history | Never smoker | 60.1 (37.4, 167.8) | 72.9% (56.6%, 83.9%) | 68.9% (51.3%, 81.2%) | 54.7% (34.5%, 71%) | 0.32 |
| Ever smoker | NA | 100% (100%, 100%) | 75.0% (12.8%, 96.1%) | 75.0% (12.8%, 96.1%) | ||
| LC according to race | White | 99.0 (51.8, 167.8) | 79.2% (64.5%, 88.4%) | 76.6% (61.3%, 86.5%) | 60.0% (40.3%, 75%) | 0.56 |
| Nonwhite | 60.1 (3.1, 60.1) | 85.2% (51.9.4%, 96.2%) | 63.9% (17.5%, 89.2%) | 63.9% (17.5%, 89.2%) | ||
| LC according to previous radiation | No | 60.1 (37.4, 114.3) | 79.3% (61.3%, 89.6%) | 71.3% (51.3%, 84.2%) | 59.1% (35.7%, 76.5%) | 0.42 |
| Yes | 88.7 (33.3, 167.8) | 73.7% (52%, 86.7%) | 67.0% (43.0%, 82.7%) | 52.1% (26.7%, 72.4%) | ||
| LC according to tumor size (cc) | < 2 | NA | 79.1% (51.8%, 92%) | 79.1% (51.8%, 92%) | 79.1% (51.8%, 92%) | 0.59 |
| 2–4 | 60.1 (13.5, 109.6) | 80.2% (40.3%, 94.8%) | 80.2% (40.3%, 94.8%) | 64.2% (22.5%, 87.7%) | ||
| 4–6 | 99.0 (4.4, 99.0) | 83.3% (27.3%, 97.5%) | 62.5% (14.2%, 89.3%) | 62.5% (14.2%, 89.3%) | ||
| > 6 | 53.7 (33.3, 167.8) | 76.0% (55.7%, 87.9%) | 62.6% (40.9%, 78.2%) | 46.5% (24.9%, 65.6%) | ||
| LC according to radiation dose (Gy) | ≤ 13 | 32.8 (15.0, 114.3) | 59.7% (23.5%, 83.2%) | 47.8% (15.3%, 74.8%) | 17.9% (1.1%, 51.7%) | 0.08 |
| > 13 | 99.0 (51.8, 167.8) | 81.9% (68.6%, 90.0%) | 73.0% (57.0%, 83.6%) | 64.5% (46.0%, 78.1%) | ||
| LC according to radiation Rx (mo) | ≤ 6 | 88.7 (51.8, 109.6) | 79.4% (50.8%, 92.5%) | 79.4% (50.8%, 92.5%) | 69.5% (37.5%, 87.4%) | 0.98 |
| > 6 | 99.0 (35.0, 167.8) | 75.0% (58.2%, 85.9%) | 65.0% (44.7%, 79.4%) | 54.2% (28%, 74.5%) | ||
| OS | ||||||
| OS according to tumor site | Anterior cranial fossa | 49.9 (33.5, 64.9) | 90.9% (50.8%, 98.7%) | 77.9% (35.4%, 94.2%) | 46.8% (11.4%, 76.7%) | 0.06 |
| Middle cranial fossa | 88.1 (34.4, 122.6) | 100% (100%, 100%) | 80% (20.4%, 96.9%) | 80% (20.4%, 96.9%) | ||
| Posterior cranial fossa | NA | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) | ||
| Convexity | NA | 100% (100%, 100%) | 92.3% (56.6%, 98.9%) | 92.3% (56.6%, 98.9%) | ||
| Parasagittal | NA | 92.3% (56.6%, 98.9%) | 92.3% (56.6%, 98.9%) | 92.3% (56.6%, 98.9%) | ||
| Temporal | NA | 75.0% (29.8%, 93.4%) | 75.0% (29.8%, 93.4%) | 75.0% (29.8%, 93.4%) | ||
| Others | NA | 100% (100%, 100%) | 100% (100%, 100%) | 66.7% (5.4%, 94.5%) | ||
| OS according to initial symptoms | No | 88.1 (48.3, 122.6) | 100% (100%, 100%) | 93.3% (61.3%, 99.0%) | 84.0% (48.7%, 95.9%) | 0.81 |
| Yes | NA | 90.4% (76.5%, 96.3%) | 84.2% (67.9%, 92.7%) | 77.6% (59.6%, 88.3%) | ||
| OS according to age (y) | ≤ 60 | NA | 97.6% (84.3%, 99.7%) | 97.6% (84.3%, 99.7%) | 92.2% (69.6%, 98.2%) | 0.004 |
| > 60 | 88.1 (49.9, 122.6) | 92.8% (78.4%, 97.7%) | 78.9% (57.1%, 90.4%) | 68.9% (45.7%, 83.8%) | ||
| OS according to gender | Female | 122.6 (72.8, 122.6) | 96.1% (85.2%, 99.0%) | 92.1% (75.8%, 97.6%) | 82.1% (59.9%, 92.7%) | 0.55 |
| Male | NA | 94.3% (78.6%, 98.6%) | 84.9% (63.3%, 94.3%) | 80.2% (57.6%, 91.5%) | ||
| OS according to smoking history | Nonsmokers | NA | 92.7% (81.3%, 97.3%) | 83.1% (66.7%, 91.9%) | 71.8% (52.5%, 84.4%) | 0.14 |
| Ever smokers | NA | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) | ||
| OS according to race | White | NA | 93.6% (83.5%, 97.6%) | 90.8% (78.5%, 96.2%) | 84.7% (69.4%, 92.7%) | 0.38 |
| Nonwhite | NA | 100% (100%, 100%) | 71.4% (25.8%, 92.0%) | 53.6% (13.2%, 82.5%) | ||
| OS according to previous radiation | No | NA | 100% (100%, 100%) | 91.7% (70.6%, 97.9%) | 91.7% (70.6%, 97.9%) | 0.02 |
| Yes | NA | 87.0% (68.3%, 95.0%) | 81.9% (60.6%, 92.3%) | 65.0% (40.3%, 81.5%) | ||
| OS according to tumor size (cc) | < 2 | NA | 100% (100%, 100%) | 88.9% (43.3%, 98.4%) | 88.9% (43.3%, 98.4%) | 0.64 |
| 2–4 | NA | 100% (100%, 100%) | 87.5% (38.7%, 98.1%) | 75.0% (31.5%, 93.1%) | ||
| 4–6 | NA | 87.5% (38.7%, 98.1%) | 87.5% (38.7%, 98.1%) | 65.6% (15.7%, 90.9%) | ||
| > 6 | 122.6 (72.8, 173.6) | 92.2% (76.9%, 97.5%) | 88.2% (70.4%, 95.6%) | 83.6% (63.4%, 93.2%) | ||
| OS according to radiation dose (Gy) | ≤ 13 | 88.1 (33.5, 122.6) | 100% (100%, 100%) | 90.0% (47.3%, 98.5%) | 80.0% (40.9%, 94.6%) | 0.20 |
| > 13 | NA | 94.1% (84.5%, 97.8%) | 88.5% (75.0%, 94.9%) | 82.1% (65.8%, 91.1%) | ||
| OS according to radiation Rx (mo) | ≤ 6 | NA | 93.9% (77.9%, 98.4%) | 93.9% (77.9%, 98.5%) | 73.1% (37.2%, 90.5%) | 0.78 |
| > 6 | NA | 95.6% (83.4%, 98.9%) | 85.0% (66.9%, 93.7%) | 81.3% (62.3%, 91.4%) | ||
Abbreviations: LC, local control; NA, not available; OS, overall survival.
Statistically significant values have been boldfaced.